Sign in →

Test Code VEGF Vascular Endothelial Growth Factor, Plasma

Important Note

SCH NOTE**Because this must be spun at the hospital (1500 RPM) CALL FOR STAT PICKUP!! (ONE HOUR MAX TIME IS ALLOWED BETWEEN COLLECTION AND CENTRIFUGATION AT THE HOSPITAL - PLEASE PLAN ACCORDINGLY). Once specimen is spun at the hospital - Freeze specimen within 24 hours of collection - does not need to be frozen in 30 minutes.


Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Lavender-top (EDTA)

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions:

1. Immediately after specimen collection, place the tube on wet ice.

2. Centrifuge at 4° C, 1500 x g for 10 minutes.

3. Aliquot plasma into plastic vial.

4. Freeze specimen within 2 hours of collection.


Secondary ID

63019

Method Name

Electrochemiluminescence Immunoassay (ECLIA)

Reporting Name

Vascular Endothelial Growth Fctr, P

Specimen Type

Plasma EDTA

Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Plasma EDTA Frozen (preferred) 21 days
  Refrigerated  24 hours

Reject Due To

Gross hemolysis OK
Gross lipemia Reject
Gross icterus Reject
Heat-treated Reject

Clinical Information

Vascular endothelial growth factor (VEGF) is a critical modulator of angiogenesis (the growth of new blood vessels).(1) In mammals, there are 5 members of the VEGF family, each arising from different genes, with VEGF-A being the most well-studied. VEGF-A promotes angiogenesis by inducing migration of endothelial cells, promoting mitosis of endothelial cells, and upregulating matrix metalloproteinase activity.(2) VEGF-A is regulated by hypoxia, with increased expression when cells detect an environment low in oxygen. Physiologically, VEGF induces new blood vessel formation during embryonic development, after tissue injury, and in response to blocked vessels.

 

VEGF also regulates pathological vessel formation, such as in tumor growth and metastases.(3) Angiogenesis during tumor development is complex, although it is clear that VEGF plays a key role. VEGF also regulates angiogenesis in other disease states including rheumatoid arthritis, osteoarthritis, diabetes, and age-related macular degeneration. In addition, circulating concentrations of VEGF are elevated in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, a monoclonal plasma cell disorder.(4) Although the pathologic role of VEGF in POEMS is unclear, it is useful as a diagnostic marker and for assessing response to therapy.

 

In addition to the various genes in the VEGF family, VEGFA has multiple splicing variants. VEGFA 165 is the predominant isoform.(2) An internal study has demonstrated that the VEGF assay used by Mayo Clinic Laboratories is specific for the splice variant of VEGF-A 165 and does not detect other isoforms of VEGFA or other VEGF gene products.

Reference Values

≤96.2 pg/mL

Method Description

The vascular endothelial growth factor (VEGF) cytokine assay measures human cytokines in a 96-well spotted plate. The assay employs a sandwich immunoassay format where capture antibodies are coated on a single spot on the bottom of each well. Diluted samples, calibrators, and controls are added and to the plate. If present, VEGF will bind to the capture antibodies. After incubation, a solution containing detection antibodies conjugated with electrochemiluminescent labels is added. After a final incubation, a buffer is added that creates the appropriate chemical environment for electrochemiluminescence. The plate is then read on the QuickPlex SQ120. The machine applies a voltage that causes bound labels to emit measurable light. The QuickPlex SQ120 measures the intensity of emitted light and correlates it to a set of standards of known quantity via a 4-point logistics curve fitting method.(Unpublished Mayo method)

Day(s) Performed

Tuesday, Thursday

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

83520

LOINC Code Information

Test ID Test Order Name Order LOINC Value
VEGF Vascular Endothelial Growth Fctr, P 34694-0

 

Result ID Test Result Name Result LOINC Value
63019 VEGF, P 34694-0

Useful For

Evaluation of patients with suspected POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, particularly in differentiating from other forms of polyneuropathy and/or monoclonal plasma cell disorders

Interpretation

Elevated concentration of vascular endothelial growth factor (VEGF) may be consistent with a diagnosis of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome.

 

Decreasing concentrations of VEGF over time in a patient with POEMS syndrome may be consistent with a therapeutic response.